Gene therapy cures canines of inherited form of day blindness

April 21, 2010

Veterinary ophthalmology researchers from the University of Pennsylvania have used gene therapy to restore retinal cone function and day vision in two canine models of congenital achromatopsia, also called rod monochromacy or total color blindness.

Achromatopsia is a rare autosomal recessive disorder with an estimated prevalence in human beings of about 1 in 30,000 to 50,000. It primarily affects the function of the cone photoreceptors in the retina and serves as a representative model for other more common inherited retinal disorders affecting cones. Cone function is essential for , central visual acuity and most daily visual activities, which underlines the importance of the newly developed treatment.

The treatment cured younger canines regardless of the mutation that caused their achromatopsia. It was effective for the 33 months of the study and most likely is permanent; however, researchers also observed a reproducible reduction in the cone therapy success rate in dogs treated at 54 weeks of age or older.

This video is not supported by your browser at this time.
In the first segment, dogs with no vision problems negotiate the obstacle course. In part two, a dog with achromatopsia has no trouble in a dark room, but must feel his way in the light. Finally, treated dogs maneuver without trouble. Credit: University of Pennsylvania School of Veterinary Medicine

The successful therapy in dogs was documented by the restoration of the cone function using electroretinography and by objective measure of day vision behavior. The behavioral results suggest that inner and central visual pathways were able to usefully process the input from the recovered cones.

The results represent the second successful cone-directed gene replacement therapy in achromatopsia animal models and the first outside of mouse models. The targets mutations of the CNGB3 gene, the most common cause of achromatopsia in humans. Achromatopsia-affected dogs represent the only natural large animal model of CNGB3-achromatopsia.

The results hold promise for future clinical trials of cone-directed gene therapy in achromatopsia and other cone-specific disorders.

"The successful restoration of visual function with recombinant adeno-associated virus-mediated gene replacement therapy has ushered in a new era of retinal therapeutics," said András M. Komáromy, assistant professor of ophthalmology at the Penn School of Veterinary Medicine and lead author of the study.

Many vision-impairing disorders in humans result from genetic defects, and, to date, mutations have been identified in ~150 genes out of ~200 mapped retinal disease loci. This wealth of genetic information has provided fundamental understanding of the multiple and specialized roles played by photoreceptors and the retinal pigment epithelium in the visual process and how mutations in these genes result in disease. Together with the development of gene-transfer technologies, it is now possible to realistically consider the use of gene therapy to treat these previously untreatable disorders.

Explore further: First clinical trial of gene therapy for childhood blindness

Related Stories

First clinical trial of gene therapy for childhood blindness

May 1, 2007

The first clinical trial to test a revolutionary treatment for blindness in children has been announced by researchers at UCL (University College London). The trial, funded by the Department of Health, is the first of its ...

Gene therapy restores vision to mice with retinal degeneration

October 16, 2008

Massachusetts General Hospital (MGH) researchers have used gene therapy to restore useful vision to mice with degeneration of the light-sensing retinal rods and cones, a common cause of human blindness. Their report, appearing ...

Cats' eye diseases genetically linked to diseases in humans

March 4, 2009

About one in 3,500 people are affected with retinitis pigmentosa (RP), a disease of the retina's visual cells that eventually leads to blindness. Now, a University of Missouri researcher has identified a genetic link between ...

The gene for day blindness in the dachshund has been found

May 27, 2009

A PhD project by Anne Caroline Wiik has discovered the genetic cause of day blindness or "cone-rod dystrophy” in the wire-haired dachshund. The disease was discovered in two litter mates in 1999 and has since been studied ...

Developing gene therapy to fight blindness

July 29, 2009

An international team of scientists and clinicians from the United States and Saudi Arabia are working to develop gene therapy for treating a rare, hereditary retinal disease. The therapy has been shown to restore lost vision ...

Recommended for you

Sixth sense: How do we sense electric fields?

October 13, 2015

A variety of animals are able to sense and react to electric fields, and living human cells will move along an electric field, for example in wound healing. Now a team lead by Min Zhao at the UC Davis Institute for Regenerative ...

A better way to read the genome

October 9, 2015

UConn researchers have sequenced the RNA of the most complicated gene known in nature, using a hand-held sequencer no bigger than a cell phone.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.